Biohaven Pharmaceutical Holding Company Ltd.

Biohaven Pharmaceutical Holding Company Ltd., a biopharmaceutical company, develops products candidates targeting neurological and neuropsychiatric diseases, and rare disorders in the United States. It offers NURTEC ODT (rimegepant) for the acute treatment of migraine, as well as developing Rimegepant for preventive treatment of migraine; Zavegepant that is in phase III clinical trials for acute and preventive treatment of migraine, as well as respiratory complications and non-migraine studies; and BHV-3100 for non-migraine indications. Show More...

  • Website https://www.biohavenpharma.com
  • Sector Healthcare
  • Industry Biotechnology
  • Last Quote 14.81 USD
  • Last Updated 30-05-2025
  • External Links Yahoo Finance Morningstar Ratios
  •   2010-12 2011-12 2012-12 2013-12 2014-12 2015-12 2016-12 2017-12 2018-12 2019-12 TTM
    Earnings Per Share USD -0.77 -4.86 -5.0 -6.15 -10.91 -12.57
    Dividends USD
    Payout Ratio % *
    Shares Mil 13.0 13.0 28.0 39.0 48.0 52.0
    Book Value Per Share * USD 4.33 1.49 2.27 2.08
    Free Cash Flow Per Share * USD -1.96 -5.46 -6.87
    Return on Assets % -531.82 -440.53 -160.08 -110.29 -166.74 -164.43
    Financial Leverage (Average) 1.65 1.57 1.11 1.92 4.37
    Return on Equity % -879.55 -695.2 -186.66 -170.33 -737.03 -584.04
    Return on Invested Capital % -879.55 -454.14 -179.93 -89.72 -682.32 -553.07
    Interest Coverage -163.79 -138.28 -19.44 -12.45 -12.74
    Current Ratio 5.74 3.03 14.49 13.94 4.96 3.89
    Quick Ratio 4.44 2.97 13.94 13.53 4.83 3.54
    Debt/Equity 0.03 0.78